Trevi Therapeutics ( (TRVI) ) has released its Q2 earnings. Here is a breakdown of the information Trevi Therapeutics presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing Haduvio, an investigational therapy for chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease, and refractory chronic cough.
In its second quarter 2025 financial report, Trevi Therapeutics announced positive topline results from its Phase 2b CORAL trial of Haduvio for treating chronic cough in IPF patients, alongside a successful $115 million underwritten offering, which extends its cash runway into 2029.
The Phase 2b CORAL trial showed that Haduvio achieved statistically significant reductions in 24-hour cough frequency across all dose groups, with the highest dose group showing a 60.2% reduction. Additionally, improvements in quality of life were noted through the Leicester Cough Questionnaire scores. The company plans to initiate a Phase 3 program in 2026 following an FDA meeting later this year.
Financially, Trevi reported a slight decrease in R&D expenses to $9.4 million and an increase in G&A expenses to $4.3 million for the quarter. Despite a net loss of $12.3 million, the company’s financial position is bolstered by its recent capital raise, ending the quarter with $203.9 million in cash and equivalents.
Looking ahead, Trevi Therapeutics is poised to advance Haduvio through late-stage development and key clinical milestones, supported by a strong financial foundation and a strategic focus on addressing the unmet needs in chronic cough treatment.